Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Brian Andrew Van Tine"'
Autor:
Jeff Charles Kremer, Bethany Cheree Prudner, Sara Elaine Stubbs Lange, Gregory Richard Bean, Matthew Bailey Schultze, Caitlyn Brook Brashears, Megan DeAnna Radyk, Nathan Redlich, Shin-Cheng Tzeng, Kenjiro Kami, Laura Shelton, Aixiao Li, Zack Morgan, John Stephen Bomalaski, Takashi Tsukamoto, Jon McConathy, Loren Scott Michel, Jason Matthew Held, Brian Andrew Van Tine
Publikováno v:
Cell Reports, Vol 18, Iss 4, Pp 991-1004 (2017)
Targeting defects in metabolism is an underutilized strategy for the treatment of cancer. Arginine auxotrophy resulting from the silencing of argininosuccinate synthetase 1 (ASS1) is a common metabolic alteration reported in a broad range of aggressi
Externí odkaz:
https://doaj.org/article/02d20fe490c24a00b6b854ec1ed68be3
Autor:
David H Aggen, David S. Hong, Jeffrey Melson Clarke, Adam Steven Asch, Emiliano Calvo, Jon Zugazagoitia, Marcus O. Butler, Victor Moreno, Andres Cervantes, Brian Andrew Van Tine, Donald P. Lawrence, Melissa Lynne Johnson, Francine Elizabeth Brophy, Robyn Broad, Martin Isabelle, Alasdair Gunn, Jean-Marc Navenot, Jose Saro, Elliot Norry, John A. Charlson
Publikováno v:
Journal of Clinical Oncology. 41:517-517
517 Background: ADP-A2M4CD8 is a specific peptide enhanced affinity receptor mixed CD4+ and CD8+ T-cell therapy targeting the cancer testis antigen MAGE-A4 and modified with addition of a CD8α co-receptor designed to provide additional functionality
Autor:
Mariela A. Blum Murphy, Jaffer A. Ajani, Brian Andrew Van Tine, Jeffrey Melson Clarke, Marcus O. Butler, Donald P. Lawrence, Melissa Lynne Johnson, Andres Cervantes, Victor Moreno, David S. Hong, Francine Elizabeth Brophy, Jean-Marc Navenot, Quan Lin, Jose Saro, Elliot Norry
Publikováno v:
Journal of Clinical Oncology. 41:349-349
349 Background: ADP-A2M4CD8 is a specific peptide enhanced affinity receptor mixed CD4+ and CD8+ T-cell therapy targeting the cancer testis antigen MAGE-A4 and modified with addition of a CD8α co-receptor designed to provide additional functionality
Autor:
Meredith McKean, Anthony W. Tolcher, James Andrew Reeves, Bartosz Chmielowski, Montaser F. Shaheen, Joseph Thaddeus Beck, Marlana M. Orloff, Neeta Somaiah, Brian Andrew Van Tine, Joseph J. Drabick, Alexander I. Spira, Kenneth O'byrne, Christos Stelios Karapetis, Steven A. Foresto, Sujana Movva, Jose Martinez, Mingyu Li, Robert Winkler, Dajun Yang, Yifan Zhai
Publikováno v:
Journal of Clinical Oncology. 40:9517-9517
9517 Background: Alrizomadlin restores TP53 function, activating p53-mediated apoptosis in tumor cells with wild-type TP53 and/or MDM2 amplification. Alrizomadlin also functions as a host immunomodulator and may restore antitumor activity in pts with
Autor:
Sandra P. D'Angelo, Steven Attia, Jean-Yves Blay, Sandra J. Strauss, Claudia Maria Valverde Morales, Albiruni Ryan Abdul Razak, Erin Van Winkle, Thejo Annareddy, Chandra Sattigari, Evangelo Diamantopoulos, Dennis Williams, Elliot Norry, Swethajit Biswas, Dejka M. Araujo, Brian Andrew Van Tine
Publikováno v:
Journal of Clinical Oncology. 40:11562-11562
11562 Background: Afami-cel is an autologous, HLA-A*02-restricted, specific peptide enhanced affinity receptor, T-cell therapy engineered to target MAGE-A4+ solid tumors. The pivotal, 2-cohort, single-arm, Phase 2, SPEARHEAD-1 trial (NCT04044768) wit
Autor:
Brian Andrew Van Tine, Matthew Ingham, Steven Attia, Christian Frederick Meyer, John Baird, Dhiren D'Silva, Kylie O'Keefe, Pius Maliakal, Mona M. Wahba, Marla Weetall, Gary K. Schwartz
Publikováno v:
Journal of Clinical Oncology. 40:11507-11507
11507 Background: Leiomyosarcoma (LMS) is one of the most common subtypes of soft tissue sarcoma and is associated with high risk of relapse and a poor prognosis for advanced disease. In preclinical LMS models, unesbulin, a microtubule polymerization
Autor:
Suzanne George, Michael C. Heinrich, Neeta Somaiah, Brian Andrew Van Tine, Robert McLeod, Abderrahmane Laadem, Ben Cheng, Satoshi Nishioka, Madan Gopal Kundu, Xiaozhong Qian, Yvonne Y. Lau, Brittany Tran, Prasanna Kumar, Ololade Dosunmu, Julia Shi, Yoichi Naito
Publikováno v:
Journal of Clinical Oncology. 40:11512-11512
11512 Background: GPR20 is selectively and abundantly expressed in GISTs, the most common sarcoma of digestive tract. DS-6157a is an anti-GPR20 antibody-drug conjugate with a novel tetrapeptide-based linker and DNA topoisomerase I inhibitor exatecan
Autor:
Sandra P. D'Angelo, Mihaela Druta, Brian Andrew Van Tine, David A. Liebner, Scott Schuetze, Michael Nathenson, Andrew P. Holmes, Jimson D'Souza, Gurpreet Singh Kapoor, Stefan Zajic, Neeta Somaiah
Publikováno v:
Journal of Clinical Oncology. 40:11500-11500
11500 Background: Lete-cel is an autologous T-cell therapy targeting NY-ESO-1 tumors using a genetically modified, high-affinity T-cell receptor. MRCLS is a sarcoma with poor response to current immunotherapy approaches and limited treatment options.
Autor:
Brian Andrew Van Tine, Joleen M. Hubbard, Monica M. Mita, Minal A. Barve, Erika P. Hamilton, Andrew J. Brenner, Frances Valdes, Daniel H. Ahn, Jason S. Starr, Joshua Pelham, Thomas Strack, Amy Yuet, Diana Yurewicz, Taunya J. Smith, Andres Machado, William Jeffery Edenfield, Aki Morikawa, Meena Okera, Nihal E. Abdulla, Zev A. Wainberg
Publikováno v:
Journal of Clinical Oncology. 40:2583-2583
2583 Background: MT-5111 is a 55kD engineered toxin body (ETB) targeting HER2 in solid tumors that binds to an epitope distinct from trastuzumab and pertuzumab, offering potential combination strategies with other HER2-targeting agents. MT-5111 may d
Autor:
Mark Andrew Dickson, Vinod Ravi, Richard F. Riedel, Kristen N. Ganjoo, Brian Andrew Van Tine, Rashmi Chugh, Lee D. Cranmer, Erlinda Maria Gordon, James Lin Chen, Martina Cathryn Murphy, Anita N. Schmid, Neil Desai, Norma Alonzo Palma, David J. Kwiatkowski, Andrew J. Wagner
Publikováno v:
Journal of Clinical Oncology. 40:11574-11574
11574 Background: Malignant perivascular epithelioid cell tumor (PEComa) is a rare and aggressive sarcoma. nab-Sirolimus is an albumin-bound intravenous (IV) mTOR inhibitor (mTORi) approved for the treatment of adult patients with locally advanced un